公开(公告)号：WO2012148550A1

公开(公告)日：2012-11-01

申请号：PCT/US2012/026593

申请日：2012-02-24

Applicant: MYREXIS, INC. ,  BAJJI, Ashok, C. ,  TANGALLAPALLY, Rajendra, P. ,  KIM, In, Chul ,  KIM, Se, Ho ,  PARKER, Daniel, P. ,  TROVATO, Richard ,  PAPAC, Damon, I. ,  YAGER, Kraig ,  BAICHWAL, Vijay, R.

Inventor： BAJJI, Ashok, C. ,  TANGALLAPALLY, Rajendra, P. ,  KIM, In, Chul ,  KIM, Se, Ho ,  PARKER, Daniel, P. ,  TROVATO, Richard ,  PAPAC, Damon, I. ,  YAGER, Kraig ,  BAICHWAL, Vijay, R.

IPC: A61K31/52 ,  C07D473/00

CPC classification number: C07D473/34 ,  A61K31/52

Abstract: The present invention provides compounds, pharmaceutical compositions and medicaments comprising such compounds, and the use of these compounds, compositions, and medicaments in methods of treating diseases and disorders such as cancers.

Abstract translation: 本发明提供了包含这些化合物的化合物，药物组合物和药物，以及这些化合物，组合物和药物在治疗诸如癌症的疾病和病症的方法中的用途。

公开(公告)号：WO2011109441A1

公开(公告)日：2011-09-09

申请号：PCT/US2011/026752

申请日：2011-03-01

Applicant: MYREXIS, INC. ,  WILLARDSEN, Adam, J. ,  LOCKMAN, Jeffrey, W. ,  MURPHY, Brett, R. ,  JUDD, Weston, R. ,  KIM, In Chul ,  KIM, Se-Ho ,  ZIGAR, Daniel, Feodore ,  YAGER, Kraig, M. ,  FLEISCHER, Tracey, C. ,  TERRY-LORENZO, Ryan, T. ,  BONIFACE, Jay, J. ,  PARKER, Daniel, P. ,  MCALEXANDER, Ian, A. ,  BURSAVICH, Matthew, Gregory ,  DASTRUP, David, M.

Inventor： WILLARDSEN, Adam, J. ,  LOCKMAN, Jeffrey, W. ,  MURPHY, Brett, R. ,  JUDD, Weston, R. ,  KIM, In Chul ,  KIM, Se-Ho ,  ZIGAR, Daniel, Feodore ,  YAGER, Kraig, M. ,  FLEISCHER, Tracey, C. ,  TERRY-LORENZO, Ryan, T. ,  BONIFACE, Jay, J. ,  PARKER, Daniel, P. ,  MCALEXANDER, Ian, A. ,  BURSAVICH, Matthew, Gregory ,  DASTRUP, David, M.

IPC: A01N47/28

CPC classification number: C07D213/75 ,  C07B2200/05 ,  C07C275/28 ,  C07C275/30 ,  C07C275/32 ,  C07C275/34 ,  C07C275/40 ,  C07C311/21 ,  C07C311/47 ,  C07D209/14 ,  C07D213/42 ,  C07D213/53 ,  C07D213/61 ,  C07D213/64 ,  C07D213/65 ,  C07D213/68 ,  C07D213/71 ,  C07D213/73 ,  C07D215/46 ,  C07D231/12 ,  C07D231/40 ,  C07D233/64 ,  C07D235/06 ,  C07D237/20 ,  C07D261/08 ,  C07D307/14 ,  C07D307/48 ,  C07D307/52 ,  C07D317/58 ,  C07D333/20 ,  C07D333/22 ,  C07D401/12 ,  C07D409/12 ,  C07D413/12 ,  C07D417/12 ,  C07D471/04

Abstract: The invention relates to compounds, pharmaceutical compositions and methods useful for treating cancer, systemic or chronic inflammation, rheumatoid arthritis, diabetes, obesity, T-cell mediated autoimmune disease, ischemia, and other complications associated with these diseases and disorders.

Abstract translation: 本发明涉及可用于治疗癌症，全身或慢性炎症，类风湿性关节炎，糖尿病，肥胖症，T细胞介导的自身免疫疾病，缺血以及与这些疾病和病症相关的其它并发症的化合物，药物组合物和方法。

公开(公告)号：WO2009128677A3

公开(公告)日：2009-10-22

申请号：PCT/KR2009/002017

申请日：2009-04-17

Applicant: SAMSUNG ELECTRONICS CO., LTD. ,  LIM, Jun-Sung ,  KIM, Se-Ho ,  KANG, Hee-Won ,  CHOI, Ho-Kyu ,  CHO, Jae-Weon

Inventor： LIM, Jun-Sung ,  KIM, Se-Ho ,  KANG, Hee-Won ,  CHOI, Ho-Kyu ,  CHO, Jae-Weon

IPC: H04W72/04 ,  H04W16/12

Abstract: A resource allocation for reducing overhead in a mobile communication system is provided. An operating method of a base station for changing a fixed resource allocation to reduce overhead in a mobile communication system includes calculating a total amount of resources allocated to a corresponding subframe in a period of a corresponding fixed allocation resource; when the total amount of the resources allocated to the corresponding subframe is greater than a threshold, temporarily canceling one or more corresponding fixed allocation resources to make the total amount of the resources allocated to the corresponding subframe less than or equal to the threshold; and reallocating the one or more canceled fixed allocation resources according to a corresponding rule.

公开(公告)号：WO2007134298A2

公开(公告)日：2007-11-22

申请号：PCT/US2007/068899

申请日：2007-05-14

Applicant: MYRIAD GENETICS, INC. ,  BAJJI, Ashok C. ,  KIM, Se-ho ,  MARKOVITZ, Benjamin ,  TROVATO, Richard ,  TANGALLAPALLY, Rajendra ,  ANDERSON, Mark B. ,  WETTSTEIN, Daniel ,  SHENDEROVICH, Mark ,  VANECKO, John A.

Inventor： BAJJI, Ashok C. ,  KIM, Se-ho ,  MARKOVITZ, Benjamin ,  TROVATO, Richard ,  TANGALLAPALLY, Rajendra ,  ANDERSON, Mark B. ,  WETTSTEIN, Daniel ,  SHENDEROVICH, Mark ,  VANECKO, John A.

IPC: B01D46/10

CPC classification number: A61K31/52 ,  A61K31/522 ,  C07D473/34

Abstract: The invention relates to compounds of Formulae I-III and their therapeutic uses.

Abstract translation: 本发明涉及式I-III的化合物及其治疗用途。

公开(公告)号：WO2011040668A1

公开(公告)日：2011-04-07

申请号：PCT/KR2009/006380

申请日：2009-11-02

Applicant: GREEN CROSS CORPORATION ,  KIM, Se-Ho ,  CHANG, Ki Hwan ,  HONG, Kwang-Won ,  SHIN, Yong-Won ,  KIM, Min-Soo ,  LEE, Hae-Won ,  SHIN, Yong Nam ,  RYOO, Kyung Hwan ,  SEO, Dong Hyuck

Inventor： KIM, Se-Ho ,  CHANG, Ki Hwan ,  HONG, Kwang-Won ,  SHIN, Yong-Won ,  KIM, Min-Soo ,  LEE, Hae-Won ,  SHIN, Yong Nam ,  RYOO, Kyung Hwan ,  SEO, Dong Hyuck

IPC: C07K16/28

CPC classification number: C07K16/2863 ,  C07K2317/565

Abstract: Provided are antibodies specifically binding to the epidermal growth factor receptor (EGFR) which are effective for the treatment of EGFR-mediated cancers.

Abstract translation: 提供了与EGFR介导的癌症治疗有效的表皮生长因子受体（EGFR）特异性结合的抗体。

公开(公告)号：WO2010002180A3

公开(公告)日：2010-04-15

申请号：PCT/KR2009003555

申请日：2009-06-30

Applicant: SAMSUNG ELECTRONICS CO LTD ,  KIM SE-HO ,  OH CHANG-YOON ,  LIM JUN-SUNG ,  KANG HEE-WON

Inventor： KIM SE-HO ,  OH CHANG-YOON ,  LIM JUN-SUNG ,  KANG HEE-WON

IPC: H04B7/26

CPC classification number: H04L1/1887 ,  H04W72/04 ,  H04W72/042

Abstract: Apparatuses of a base station and terminal in a wireless communication system and their operating methods are provided. An operating method of a base station in a broadband wireless communication system includes determining whether to relocate at least one persistently allocated resource, when it is determined to relocate the at least one persistently allocated resource, relocating the at least one persistently allocated resource, generating a resource relocation Information Element (IE) indicative of the resource relocation using an offset of a Resource Block (RB), and transmitting the resource relocation IE.

Abstract translation: 提供了无线通信系统中的基站和终端的设备及其操作方法。 宽带无线通信系统中的基站的操作方法包括：当确定要重新定位所述至少一个持久分配的资源时，确定是否重新定位至少一个持久分配的资源，重新定位所述至少一个持久分配的资源，生成 指示使用资源块（RB）的偏移的资源重新定位的资源重新定位信息元素（IE），以及发送资源重新定位IE。

公开(公告)号：WO2009069917A1

公开(公告)日：2009-06-04

申请号：PCT/KR2008/006868

申请日：2008-11-21

Applicant: GREEN CROSS CORPORATION ,  KIM, Se-Ho ,  HONG, Kwang-Won ,  SHIN, Yong-Nam ,  SHIN, Yong-Won ,  CHANG, Ki-Hwan ,  RYOO, Kyung-Hwan ,  CHOI, Jin-Seol ,  KIM, Pan-Kyung ,  BONG, Ki-Tae ,  SEO, Dong-Hyuck ,  OH, Sun-Jeong

Inventor： KIM, Se-Ho ,  HONG, Kwang-Won ,  SHIN, Yong-Nam ,  SHIN, Yong-Won ,  CHANG, Ki-Hwan ,  RYOO, Kyung-Hwan ,  CHOI, Jin-Seol ,  KIM, Pan-Kyung ,  BONG, Ki-Tae ,  SEO, Dong-Hyuck ,  OH, Sun-Jeong

IPC: A61K38/16 ,  A61K39/395

CPC classification number: A61K38/215 ,  A61K39/42 ,  A61K2039/505 ,  C07K16/082 ,  C07K2317/56 ,  A61K2300/00

Abstract: The present invention provides a use of a human antibody against a hepatitis B virus (HBV) surface antigen (HBsAg). The antibody exhibits an excellent HBV neutralizing ability, and thus, is useful for the prevention or treatment of the HBV infection or a disease caused thereby.

Abstract translation: 本发明提供了针对乙型肝炎病毒（HBV）表面抗原（HBsAg）的人抗体的用途。 抗体表现出优异的HBV中和能力，因此可用于预防或治疗HBV感染或由此引起的疾病。

公开(公告)号：WO2007076161A3

公开(公告)日：2007-11-08

申请号：PCT/US2006049558

申请日：2006-12-27

Applicant: MYRIAD GENETICS INC ,  BAJJI ASHOK C ,  KIM SE-HO ,  TROVATO RICHARD ,  MCHUGH ROBERT J ,  MARKOVITZ BENJAMIN ,  ANDERSON MARK B

Inventor： BAJJI ASHOK C ,  KIM SE-HO ,  TROVATO RICHARD ,  MCHUGH ROBERT J ,  MARKOVITZ BENJAMIN ,  ANDERSON MARK B

IPC: C07D413/00

CPC classification number: C07D417/12 ,  C07D413/12 ,  C07D413/14 ,  C07D471/04

Abstract: Methods and pharmaceutical compositions for treating and/or delaying the onset of viral infection are provided. The pharmaceutical compositions include compounds having an oxazole core. Additionally, the compositions can be used to treat cardiovascular disorders and cancer.

Abstract translation: 提供了用于治疗和/或延迟病毒感染发作的方法和药物组合物。 药物组合物包括具有恶唑核心的化合物。 另外，该组合物可用于治疗心血管疾病和癌症。

公开(公告)号：WO2006135383A2

公开(公告)日：2006-12-21

申请号：PCT/US2005/027730

申请日：2005-08-04

Applicant: MYRIAD GENETICS, INC. ,  BAJJI, Ashok ,  MORHAM, Scott ,  ANDERSON, Mark B. ,  MCHUGH, Robert J. ,  TROVATO, Richard ,  WEINER, Warren S. ,  KIM, Se-Ho

Inventor： BAJJI, Ashok ,  MORHAM, Scott ,  ANDERSON, Mark B. ,  MCHUGH, Robert J. ,  TROVATO, Richard ,  WEINER, Warren S. ,  KIM, Se-Ho

IPC: A61K31/416

CPC classification number: C07D403/12 ,  C07D401/12 ,  C07D401/14 ,  C07D405/12 ,  C07D405/14 ,  C07D417/12 ,  C07D417/14

Abstract: Methods and pharmaceutical compositions for treating and/or delaying the onset of viral infection are provided. The pharmaceutical compositions include compounds having an indazole core. Additionally, the compositions can be used to treat cardiovascular disorders and cancer.

Abstract translation: 提供了用于治疗和/或延缓病毒感染发作的方法和药物组合物。 药物组合物包括具有吲唑核心的化合物。 另外，组合物可用于治疗心血管疾病和癌症。

公开(公告)号：WO2010074540A3

公开(公告)日：2010-11-11

申请号：PCT/KR2009007804

申请日：2009-12-24

Applicant: SAMYANG CORP ,  KIM SE-HO ,  SON JI-YEON ,  LA MUHN-HO ,  CHOI SUNG-WON ,  SEO MIN-HYO

Inventor： KIM SE-HO ,  SON JI-YEON ,  LA MUHN-HO ,  CHOI SUNG-WON ,  SEO MIN-HYO

IPC: A61K9/127 ,  A61K31/353 ,  A61K31/56 ,  A61K31/70 ,  A61K31/7105 ,  A61K31/711 ,  A61K39/21 ,  A61K39/235

CPC classification number: A61K9/1075 ,  A61K9/0019 ,  A61K31/353 ,  A61K31/56 ,  A61K31/70 ,  A61K31/7105 ,  A61K31/711

Abstract: Disclosed is a pharmaceutical composition containing an anionic drug, characterised in that it comprises: an anionic drug as an active component; a cationic lipid; and an amphiphilic block copolymer, and in that the anionic drug forms a complex with the cationic lipid, and the complex is enclosed within a micelle structure of the amphiphilic block copolymer. Also disclosed is a production method for this pharmaceutical composition. The pharmaceutical composition is advantageous in that it can improve the efficacy of anionic drugs since it allows delivery into cells and it can increase the stability of anionic drugs in the blood or in body fluids.

Abstract translation: 公开了含有阴离子药物的药物组合物，其特征在于它包含：阴离子药物作为活性组分; 阳离子脂质; 和两亲嵌段共聚物，并且阴离子药物与阳离子脂质形成络合物，并且该络合物被包封在两亲嵌段共聚物的胶束结构内。 还公开了该药物组合物的生产方法。 该药物组合物的优点在于它可以改善阴离子药物的功效，因为它允许递送到细胞中，并且它可以增加阴离子药物在血液或体液中的稳定性。